C5 and cancer: Immune suppression may involve the immune checkpoint pathway (Fig. 6d), whereby c5, c8, and c9 subtypes tend to show high expression of ligands such as PDL1 and PDL2 (presumably expressed by cancer cells), as well as high expression of the corresponding receptors associated with T cells.